With the acquisition, Piramal will fully embed Yapan’s advanced large molecule capabilities into its integrated service offering
Piramal Pharma to acquire remaining 26% stake in Yapan Bio
Published ·
Keep reading
Related stories


Published ·
With the acquisition, Piramal will fully embed Yapan’s advanced large molecule capabilities into its integrated service offering
Keep reading

